\-\ Texto\\:\\ \ \(0\)\
\-\ mild\\ left\\ buccal\\ swelling\\.\\ there\\ is\\ a\\ 20\\ x\\ 8\\ mm\\ region\\ of\\ exposed\\ bone\\ and\\ necrotic\\ tissue\\ at\\ the\\ crest\\ of\\ the\\ posterior\\ mandibular\\ ridge\\ on\\ the\\ left\\.\ \(0\)\
\-\ debridement\\ of\\ necrotic\\ bone\\ with\\ plate\\ reconstruction\\.\ \(0\)\
\-\ \\â\\€\\¢\\ permeative\\ lytic\\ destruction\\ in\\ the\\ posterior\\ body\\ and\\ angle\\ of\\ the\\ left\\ mandible\\.\\ \ \(0\)\
\-\ \\â\\€\\¢\\ associated\\ pathologic\\ fracture\\ at\\ the\\ angle\\ of\\ the\\ left\\ mandible\\ showing\\ 3\\ mm\\ lateral\\ displacement\\ and\\ foreshortening\\.\ \(0\)\
\-\ bisphosphonate\\-related\\ osteonecrosis\\ of\\ the\\ jaw\ \(1\)\
\-\ \\â\\€\\¢\\ metastatic\\ disease\ \(13\)\
\-\ \\â\\€\\¢\\ bisphosphonate\\-related\\ osteonecrosis\\ of\\ the\\ jaw\ \(0\)\
\-\ \\â\\€\\¢\\ osteoradionecrosis\ \(0\)\
\-\ \\â\\€\\¢\\ primary\\ bone\\ neoplasm\ \(0\)\
\-\ 79\\ y\\.o\\.\\ woman\\ reported\\ drainage\\ around\\ mobile\\ teeth\\ 18\\ and\\ 19\\.\\ antibiotics\\ were\\ initiated\\,\\ and\\ these\\ teeth\\ were\\ easily\\ extracted\\ by\\ her\\ dentist\\.\\ after\\ debridement\\ of\\ associated\\ chronic\\ periodontal\\ disease\\,\\ the\\ underlying\\ bone\\ was\\ noted\\ to\\ be\\ highly\\ abnormal\\ in\\ appearance\\.\\ the\\ patient\\ has\\ a\\ past\\ medical\\ history\\ of\\ crohn\\â\\€\\™s\\ disease\\ necessitating\\ colectomy\\,\\ and\\ she\\ has\\ been\\ on\\ steroid\\ medications\\ for\\ most\\ of\\ her\\ life\\.\\ she\\ also\\ carries\\ a\\ diagnosis\\ of\\ osteoporosis\\ and\\ was\\ started\\ on\\ oral\\ bisphosphonate\\ \\(ibandronate\\)\\ therapy\\ several\\ years\\ ago\ \(0\)\
\-\ bisphosphonate\\-related\\ osteonecrosis\\ of\\ the\\ jaw\\ \\(bronj\\)\\ is\\ an\\ uncommon\\ complication\\ of\\ long\\-term\\ bisphosphonate\\ therapy\\ for\\ osteoporosis\\.\\ the\\ majority\\ \\(\\>90\\%\\)\\ of\\ reported\\ cases\\ of\\ bronj\\ have\\ been\\ in\\ patients\\ receiving\\ bisphosphonate\\ therapy\\ for\\ malignancy\\ \\(watts\\ and\\ diab\\,\\ 2010\\)\\.\\ \ \(0\)\
\-\ predisposing\\ factors\\ to\\ the\\ development\\ of\\ bronj\\ include\\ dose\\ and\\ duration\\ of\\ bisphosphonate\\ therapy\\,\\ age\\,\\ corticosteroid\\ therapy\\,\\ immune\\ compromise\\,\\ periodontal\\ disease\\,\\ surgery\\,\\ and\\ trauma\\ \\(chaturvedi\\ et\\ al\\.\\,\\ 2010\\;\\ khan\\,\\ 2010\\)\\.\\ \ \(0\)\
\-\ a\\ mouse\\ model\\ for\\ studying\\ bronj\\-like\\ disease\\ uses\\ an\\ amino\\-bisphosphonate\\ and\\ methotrexate\\ to\\ induce\\ the\\ changes\\ characteristic\\ of\\ bronj\\.\\ these\\ changes\\ are\\ associated\\ with\\ alterations\\ in\\ the\\ activity\\ of\\ specific\\ t\\ cell\\ subsets\\ \\(kikuiri\\ et\\ al\\.\\,\\ 2010\\)\\.\\ \ \(0\)\
\-\ scintigraphic\\ studies\\ demonstrate\\ that\\ bisphosphonates\\ significantly\\ decrease\\ bone\\ turnover\\ in\\ the\\ mandible\\ which\\ may\\ contribute\\ to\\ the\\ pathophysiology\\ of\\ bronj\\ as\\ well\\ \\(van\\ den\\ wyngaert\\ et\\ al\\.\\,\\ 2010\\)\\.\\ \ \(0\)\
\-\ the\\ diagnosis\\ of\\ bronj\\ is\\ made\\ clinically\\ after\\ local\\ malignancy\\ is\\ excluded\\ \\(khan\\,\\ 2010\\)\\.\\ \ \(0\)\
\-\ references\\:\\ \ \(0\)\
\-\ chaturvedi\\ p\\,\\ pai\\ ps\\,\\ chaukar\\ da\\,\\ gupta\\ s\\,\\ d\\'cruz\\ ak\\.\\ bisphosphonate\\ induced\\ osteonecrosis\\ of\\ the\\ jaw\\ masquerading\\ as\\ tumor\\:\\ a\\ word\\ of\\ caution\\ for\\ oral\\ surgeons\\ and\\ oncologists\\.\\ eur\\ j\\ surg\\ oncol\\.\\ 2010\\ jan\\ 11\\.\\ \\[epub\\ ahead\\ of\\ print\\]\\ pubmed\\ pmid\\:\\ 20071132\\.\ \(0\)\
\-\ khan\\ a\\.\\ osteonecrosis\\ of\\ the\\ jaw\\ and\\ bisphosphonates\\.\\ bmj\\.\\ 2010\\ feb\\ 2\\;340\\:c246\\.\\ doi\\:\\ 10\\.1136\\/bmj\\.c246\\.\\ pubmed\\ pmid\\:\\ 20124367\ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ kikuiri\\ t\\,\\ kim\\ i\\,\\ yamaza\\ t\\,\\ akiyama\\ k\\,\\ zhang\\ q\\,\\ li\\ y\\,\\ chen\\ c\\,\\ chen\\ w\\,\\ wang\\ s\\,\\ le\\ ad\\,\\ shi\\ s\\.\\ cell\\-based\\ immunotherapy\\ with\\ mesenchymal\\ stem\\ cells\\ cures\\ bisphosphonate\\-related\\ osteonecrosis\\ of\\ the\\ jaw\\-like\\ disease\\ in\\ mice\\.\\ j\\ bone\\ miner\\ res\\.\\ 2010\\ jan\\ 29\\.\\ \\[epub\\ ahead\\ of\\ print\\]\\ pubmed\\ pmid\\:\\ 20200952\\.\ \(0\)\
\-\ van\\ den\\ wyngaert\\ t\\,\\ huizing\\ mt\\,\\ fossion\\ e\\,\\ vermorken\\ jb\\.\\ scintigraphic\\ evaluation\\ of\\ mandibular\\ bone\\ turnover\\ in\\ patients\\ with\\ solid\\ tumors\\ receiving\\ zoledronic\\ acid\\.\\ oral\\ oncol\\.\\ 2010\\ mar\\;46\\(3\\)\\:214\\-8\\.\\ epub\\ 2010\\ feb\\ 6\\.\\ pubmed\\ pmid\\:\\ 20138570\\.\ \(0\)\
\-\ watts\\ nb\\,\\ diab\\ dl\\.\\ long\\-term\\ use\\ of\\ bisphosphosphonates\\ in\\ osteoporosis\\.\\ j\\.\\ clin\\ endocrinol\\ metab\\.\\ 2010\\ feb\\ 19\\.\\ \\[epub\\ ahead\\ of\\ print\\]\\ pubmed\\ pmid\\:\\ 20173017\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ bisphosphonate\\:\\ 0\\.39400655855518363\ \(0\)\
\-\ 2010\\:\\ 0\\.3581453258827028\ \(0\)\
\-\ bronj\\:\\ 0\\.3135670300969586\ \(0\)\
\-\ jaw\\:\\ 0\\.18529834564900874\ \(0\)\
\-\ osteonecrosis\\:\\ 0\\.1836143189823622\ \(0\)\
\-\ of\\:\\ 0\\.1644474041060123\ \(0\)\
\-\ pubmed\\:\\ 0\\.15918221390883158\ \(0\)\
\-\ pmid\\:\\ 0\\.15370358493049233\ \(0\)\
\-\ epub\\:\\ 0\\.15195207845440392\ \(0\)\
\-\ the\\:\\ 0\\.12296151857766731\ \(0\)\
\-\ khan\\:\\ 0\\.12088778705417477\ \(0\)\
\-\ ahead\\:\\ 0\\.12088778705417477\ \(0\)\
\-\ bone\\:\\ 0\\.10698477437316777\ \(0\)\
\-\ print\\:\\ 0\\.10681193500011071\ \(0\)\
\-\ feb\\:\\ 0\\.09660102939973533\ \(0\)\
\-\ watts\\:\\ 0\\.08959058002770245\ \(0\)\
\-\ diab\\:\\ 0\\.08959058002770245\ \(0\)\
\-\ chaturvedi\\:\\ 0\\.08959058002770245\ \(0\)\
\-\ kikuiri\\:\\ 0\\.08959058002770245\ \(0\)\
\-\ wyngaert\\:\\ 0\\.08959058002770245\ \(0\)\
\-\ c246\\:\\ 0\\.08959058002770245\ \(0\)\
\-\ osteoporosis\\:\\ 0\\.0895363314706757\ \(0\)\
\-\ mandible\\:\\ 0\\.08885103475231909\ \(0\)\
\-\ den\\:\\ 0\\.08560858211128697\ \(0\)\
\-\ therapy\\:\\ 0\\.08046996787579869\ \(0\)\
\-\ periodontal\\:\\ 0\\.07728742636403314\ \(0\)\
\-\ chen\\:\\ 0\\.07728742636403314\ \(0\)\
\-\ and\\:\\ 0\\.07524502590397271\ \(0\)\
\-\ turnover\\:\\ 0\\.07481931379462123\ \(0\)\
\-\ bmj\\:\\ 0\\.07481931379462123\ \(0\)\
\-\ oncol\\:\\ 0\\.07378458763586626\ \(0\)\
\-\ bisphosphonates\\:\\ 0\\.07199404131078647\ \(0\)\
\-\ disease\\:\\ 0\\.07054751098142284\ \(0\)\
\-\ van\\:\\ 0\\.06801204339437097\ \(0\)\
\-\ oral\\:\\ 0\\.06730169461678966\ \(0\)\
\-\ jan\\:\\ 0\\.06697731723561602\ \(0\)\
\-\ et\\:\\ 0\\.06582734288292143\ \(0\)\
\-\ scintigraphic\\:\\ 0\\.06367288556353264\ \(0\)\
\-\ teeth\\:\\ 0\\.06176611521633624\ \(0\)\
\-\ mandibular\\:\\ 0\\.06120477299412073\ \(0\)\
\-\ debridement\\:\\ 0\\.06120477299412073\ \(0\)\
\-\ receiving\\:\\ 0\\.05817700230011356\ \(0\)\
\-\ in\\:\\ 0\\.05574532777897087\ \(0\)\
\-\ necrotic\\:\\ 0\\.054534858892324255\ \(0\)\
\-\ angle\\:\\ 0\\.0491382769324489\ \(0\)\
\-\ osteoradionecrosis\\:\\ 0\\.04479529001385123\ \(0\)\
\-\ ibandronate\\:\\ 0\\.04479529001385123\ \(0\)\
\-\ studying\\:\\ 0\\.04479529001385123\ \(0\)\
\-\ subsets\\:\\ 0\\.04479529001385123\ \(0\)\
\-\ pai\\:\\ 0\\.04479529001385123\ \(0\)\
\-\ chaukar\\:\\ 0\\.04479529001385123\ \(0\)\
\-\ masquerading\\:\\ 0\\.04479529001385123\ \(0\)\
\-\ oncologists\\:\\ 0\\.04479529001385123\ \(0\)\
\-\ 20124367\\:\\ 0\\.04479529001385123\ \(0\)\
\-\ yamaza\\:\\ 0\\.04479529001385123\ \(0\)\
\-\ akiyama\\:\\ 0\\.04479529001385123\ \(0\)\
\-\ cures\\:\\ 0\\.04479529001385123\ \(0\)\
\-\ mice\\:\\ 0\\.04479529001385123\ \(0\)\
\-\ huizing\\:\\ 0\\.04479529001385123\ \(0\)\
\-\ fossion\\:\\ 0\\.04479529001385123\ \(0\)\
\-\ vermorken\\:\\ 0\\.04479529001385123\ \(0\)\
\-\ zoledronic\\:\\ 0\\.04479529001385123\ \(0\)\
\-\ bisphosphosphonates\\:\\ 0\\.04479529001385123\ \(0\)\
\-\ 20173017\\:\\ 0\\.04479529001385123\ \(0\)\
\-\ 19\\:\\ 0\\.04436405444352957\ \(0\)\
\-\ associated\\:\\ 0\\.04429130007599697\ \(0\)\
\-\ zhang\\:\\ 0\\.042804291055643484\ \(0\)\
\-\ shi\\:\\ 0\\.042804291055643484\ \(0\)\
\-\ nb\\:\\ 0\\.042804291055643484\ \(0\)\
\-\ endocrinol\\:\\ 0\\.042804291055643484\ \(0\)\
\-\ metab\\:\\ 0\\.042804291055643484\ \(0\)\
\-\ for\\:\\ 0\\.042449219416174376\ \(0\)\
\-\ malignancy\\:\\ 0\\.04193968722595071\ \(0\)\
\-\ ps\\:\\ 0\\.0413916548137261\ \(0\)\
\-\ 340\\:\\ 0\\.0413916548137261\ \(0\)\
\-\ immunotherapy\\:\\ 0\\.0413916548137261\ \(0\)\
\-\ miner\\:\\ 0\\.0413916548137261\ \(0\)\
\-\ reported\\:\\ 0\\.04034937491542836\ \(0\)\
\-\ mm\\:\\ 0\\.040091764991334954\ \(0\)\
\-\ foreshortening\\:\\ 0\\.03940065585551836\ \(0\)\
\-\ dentist\\:\\ 0\\.03940065585551836\ \(0\)\
\-\ gupta\\:\\ 0\\.03940065585551836\ \(0\)\
\-\ caution\\:\\ 0\\.03940065585551836\ \(0\)\
\-\ extracted\\:\\ 0\\.03864371318201657\ \(0\)\
\-\ induce\\:\\ 0\\.03864371318201657\ \(0\)\
\-\ alterations\\:\\ 0\\.03864371318201657\ \(0\)\
\-\ ak\\:\\ 0\\.03864371318201657\ \(0\)\
\-\ left\\:\\ 0\\.03822031335225149\ \(0\)\
\-\ model\\:\\ 0\\.037409656897310614\ \(0\)\
\-\ wang\\:\\ 0\\.037409656897310614\ \(0\)\
\-\ mt\\:\\ 0\\.037409656897310614\ \(0\)\
\-\ jb\\:\\ 0\\.037409656897310614\ \(0\)\
\-\ buccal\\:\\ 0\\.03642428198435661\ \(0\)\
\-\ permeative\\:\\ 0\\.03642428198435661\ \(0\)\
\-\ necessitating\\:\\ 0\\.03642428198435661\ \(0\)\
\-\ eur\\:\\ 0\\.03642428198435661\ \(0\)\
\-\ kim\\:\\ 0\\.03642428198435661\ \(0\)\
\-\ res\\:\\ 0\\.03642428198435661\ \(0\)\
\-\ exposed\\:\\ 0\\.03599702065539324\ \(0\)\
\-\ word\\:\\ 0\\.035603978333370236\ \(0\)\
\-\ mar\\:\\ 0\\.035603978333370236\ \(0\)\
\-\ her\\:\\ 0\\.03499905744043051\ \(0\)\
\-\ crest\\:\\ 0\\.034584384413475854\ \(0\)\
\-\ carries\\:\\ 0\\.034584384413475854\ \(0\)\
\-\ mouse\\:\\ 0\\.034584384413475854\ \(0\)\
\-\ da\\:\\ 0\\.034286692808293245\ \(0\)\
\-\ predisposing\\:\\ 0\\.03400602169718549\ \(0\)\
\-\ changes\\:\\ 0\\.033857060603377204\ \(0\)\
\-\ colectomy\\:\\ 0\\.03374052960163977\ \(0\)\
\-\ uses\\:\\ 0\\.03374052960163977\ \(0\)\
\-\ she\\:\\ 0\\.03334826634275387\ \(0\)\
\-\ ridge\\:\\ 0\\.033249079023683695\ \(0\)\
\-\ contribute\\:\\ 0\\.033249079023683695\ \(0\)\
\-\ ad\\:\\ 0\\.033249079023683695\ \(0\)\
\-\ pathophysiology\\:\\ 0\\.03280237051039384\ \(0\)\
\-\ mesenchymal\\:\\ 0\\.03280237051039384\ \(0\)\
\-\ been\\:\\ 0\\.032638762459710785\ \(0\)\
\-\ cell\\:\\ 0\\.03204688105549728\ \(0\)\
\-\ doi\\:\\ 0\\.032015022738977744\ \(0\)\
\-\ corticosteroid\\:\\ 0\\.031664130097421264\ \(0\)\
\-\ these\\:\\ 0\\.03163533416798171\ \(0\)\
\-\ patients\\:\\ 0\\.03151515953828602\ \(0\)\
\-\ methotrexate\\:\\ 0\\.03149765965960026\ \(0\)\
\-\ immune\\:\\ 0\\.03118074921335073\ \(0\)\
\-\ le\\:\\ 0\\.03088305760816812\ \(0\)\
\-\ surgeons\\:\\ 0\\.030740716986098468\ \(0\)\
\-\ is\\:\\ 0\\.0306837386928567\ \(0\)\
\-\ initiated\\:\\ 0\\.030602386497060364\ \(0\)\
\-\ compromise\\:\\ 0\\.030209344175037366\ \(0\)\
\-\ surg\\:\\ 0\\.02984544382355857\ \(0\)\
\-\ 79\\:\\ 0\\.029617011584106363\ \(0\)\
\-\ stem\\:\\ 0\\.029617011584106363\ \(0\)\
\-\ clin\\:\\ 0\\.02939873531026872\ \(0\)\
\-\ reconstruction\\:\\ 0\\.02908850115005678\ \(0\)\
\-\ acid\\:\\ 0\\.02908850115005678\ \(0\)\
\-\ diagnosis\\:\\ 0\\.029041150351916158\ \(0\)\
\-\ posterior\\:\\ 0\\.02896920266566931\ \(0\)\
\-\ were\\:\\ 0\\.028877466308722986\ \(0\)\
\-\ easily\\:\\ 0\\.02801285884915095\ \(0\)\
\-\ to\\:\\ 0\\.028010531668345225\ \(0\)\
\-\ induced\\:\\ 0\\.027777114013225603\ \(0\)\
\-\ mobile\\:\\ 0\\.027626012625898616\ \(0\)\
\-\ excluded\\:\\ 0\\.027552170518235757\ \(0\)\
\-\ crohn\\:\\ 0\\.027267429446162127\ \(0\)\
\-\ after\\:\\ 0\\.027176949708341162\ \(0\)\
\-\ steroid\\:\\ 0\\.026998298663807287\ \(0\)\
\-\ duration\\:\\ 0\\.026998298663807287\ \(0\)\
\-\ li\\:\\ 0\\.026560137424432195\ \(0\)\
\-\ significantly\\:\\ 0\\.026326264289548842\ \(0\)\
\-\ dose\\:\\ 0\\.026157890961712074\ \(0\)\
\-\ 46\\:\\ 0\\.02573522954655039\ \(0\)\
\-\ plate\\:\\ 0\\.025684865949931652\ \(0\)\
\-\ has\\:\\ 0\\.025588990473209408\ \(0\)\
\-\ destruction\\:\\ 0\\.025536802241405046\ \(0\)\
\-\ complication\\:\\ 0\\.02544051665400035\ \(0\)\
\-\ majority\\:\\ 0\\.02544051665400035\ \(0\)\
\-\ on\\:\\ 0\\.025379183480131677\ \(0\)\
\-\ uncommon\\:\\ 0\\.025346082827765598\ \(0\)\
\-\ highly\\:\\ 0\\.025073212206978487\ \(0\)\
\-\ dl\\:\\ 0\\.025073212206978487\ \(0\)\
\-\ 29\\:\\ 0\\.024411992011503174\ \(0\)\
\-\ showing\\:\\ 0\\.02418531756967998\ \(0\)\
\-\ local\\:\\ 0\\.024112026543059644\ \(0\)\
\-\ decrease\\:\\ 0\\.024075787207917868\ \(0\)\
\-\ factors\\:\\ 0\\.023693866991723905\ \(0\)\
\-\ lytic\\:\\ 0\\.02359466346368216\ \(0\)\
\-\ started\\:\\ 0\\.02359466346368216\ \(0\)\
\-\ medications\\:\\ 0\\.0234974244916275\ \(0\)\
\-\ clinically\\:\\ 0\\.02327775301743263\ \(0\)\
\-\ development\\:\\ 0\\.02315650222430707\ \(0\)\
\-\ life\\:\\ 0\\.022980061412250022\ \(0\)\
\-\ pathologic\\:\\ 0\\.02295126128497403\ \(0\)\
\-\ underlying\\:\\ 0\\.022865860738963267\ \(0\)\
\-\ displacement\\:\\ 0\\.02283772079018037\ \(0\)\
\-\ characteristic\\:\\ 0\\.022645131101285323\ \(0\)\
\-\ as\\:\\ 0\\.022505826183973017\ \(0\)\
\-\ drainage\\:\\ 0\\.02243389820559655\ \(0\)\
\-\ 90\\:\\ 0\\.02238247985489273\ \(0\)\
\-\ around\\:\\ 0\\.022356971186492994\ \(0\)\
\-\ references\\:\\ 0\\.022331594346425263\ \(0\)\
\-\ with\\:\\ 0\\.021939421518770662\ \(0\)\
\-\ made\\:\\ 0\\.021603664505474417\ \(0\)\
\-\ cells\\:\\ 0\\.021581888826222046\ \(0\)\
\-\ solid\\:\\ 0\\.021474435794063954\ \(0\)\
\-\ use\\:\\ 0\\.021432104431694746\ \(0\)\
\-\ an\\:\\ 0\\.021422434892627518\ \(0\)\
\-\ 18\\:\\ 0\\.021225754422312\ \(0\)\
\-\ specific\\:\\ 0\\.021225754422312\ \(0\)\
\-\ at\\:\\ 0\\.021160031088961993\ \(0\)\
\-\ 11\\:\\ 0\\.020969843612975356\ \(0\)\
\-\ antibiotics\\:\\ 0\\.020636178164669318\ \(0\)\
\-\ tumors\\:\\ 0\\.02060046595181072\ \(0\)\
\-\ activity\\:\\ 0\\.02056501159111298\ \(0\)\
\-\ studies\\:\\ 0\\.020547379946947823\ \(0\)\
\-\ ago\\:\\ 0\\.020494861717725757\ \(0\)\
\-\ was\\:\\ 0\\.01952404861177376\ \(0\)\
\-\ neoplasm\\:\\ 0\\.019121561394766607\ \(0\)\
\-\ swelling\\:\\ 0\\.018852606143971752\ \(0\)\
\-\ cases\\:\\ 0\\.018840158969691573\ \(0\)\
\-\ body\\:\\ 0\\.018434700945417624\ \(0\)\
\-\ several\\:\\ 0\\.018377801031528654\ \(0\)\
\-\ past\\:\\ 0\\.018232874963763253\ \(0\)\
\-\ 20\\:\\ 0\\.018070800593938827\ \(0\)\
\-\ medical\\:\\ 0\\.017801953248775572\ \(0\)\
\-\ age\\:\\ 0\\.01758542725391715\ \(0\)\
\-\ primary\\:\\ 0\\.017223590532485206\ \(0\)\
\-\ years\\:\\ 0\\.017170216011060387\ \(0\)\
\-\ evaluation\\:\\ 0\\.017082527830429073\ \(0\)\
\-\ appearance\\:\\ 0\\.01688659659147366\ \(0\)\
\-\ abnormal\\:\\ 0\\.016828484580415356\ \(0\)\
\-\ region\\:\\ 0\\.016754765650206737\ \(0\)\
\-\ include\\:\\ 0\\.01666614227030635\ \(0\)\
\-\ chronic\\:\\ 0\\.01662638166744522\ \(0\)\
\-\ trauma\\:\\ 0\\.016267575393838756\ \(0\)\
\-\ fracture\\:\\ 0\\.015919476002977707\ \(0\)\
\-\ mild\\:\\ 0\\.015878498789178064\ \(0\)\
\-\ metastatic\\:\\ 0\\.015362496121950639\ \(0\)\
\-\ surgery\\:\\ 0\\.015059764877975173\ \(0\)\
\-\ noted\\:\\ 0\\.014851259565668852\ \(0\)\
\-\ tissue\\:\\ 0\\.01469380901655627\ \(0\)\
\-\ tumor\\:\\ 0\\.014651248337334605\ \(0\)\
\-\ woman\\:\\ 0\\.014588091098522923\ \(0\)\
\-\ most\\:\\ 0\\.014577643418785386\ \(0\)\
\-\ demonstrate\\:\\ 0\\.014562013460896486\ \(0\)\
\-\ may\\:\\ 0\\.01409589352009013\ \(0\)\
\-\ have\\:\\ 0\\.013992906935139994\ \(0\)\
\-\ lateral\\:\\ 0\\.013901120942684267\ \(0\)\
\-\ well\\:\\ 0\\.01356294408110596\ \(0\)\
\-\ also\\:\\ 0\\.013175454856605543\ \(0\)\
\-\ which\\:\\ 0\\.012736767516646359\ \(0\)\
\-\ that\\:\\ 0\\.012155615814653242\ \(0\)\
\-\ by\\:\\ 0\\.011894989745615942\ \(0\)\
\-\ be\\:\\ 0\\.011362842177906937\ \(0\)\
\-\ there\\:\\ 0\\.011145391192570965\ \(0\)\
\-\ history\\:\\ 0\\.010701728732976194\ \(0\)\
\-\ are\\:\\ 0\\.010628806369415768\ \(0\)\
\-\ patient\\:\\ 0\\.009110491374180038\ \(0\)\
